AstraZeneca Stock News

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer.

AstraZeneca PLC's (LSE:AZN) blockbuster immunotherapy cancer drug Imfinzi (durvalumab) has received another approval in the US. In combination with chemotherapy, patients suffering resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) can now receive Imfinzi before and after surgery.

The U.S. Food and Drug Administration approved AstraZeneca's blockbuster cancer drug, Imfinzi, for the treatment of patients with a type of non-small cell lung cancer on Thursday.

Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.

AstraZeneca said on Thursday the U.S. Food and Drug Administration (FDA) has granted its cancer drug Imfinzi a priority review for patients with limited-stage small cell lung cancer in the United States.

In a market characterized by uncertainty and volatility, it's increasingly rare to find stocks that are weathering the storm and thriving. Yet, a select few from various sectors are doing just that—hitting all-time highs even as the broader market indices attempt to regain their footing.

AstraZeneca PLC (LSE:AZN) will have to scale back plans to expand its Merseyside vaccine manufacturing site after it was revealed the government is set to cut some of the project's funding. Of the £450 million forecast to be spent to facilitate the site development, the former Tory government had promised to contribute £65 million.

The outlook for pharmaceutical stocks has been mixed in the last five years. During the pandemic, the early-movers in the vaccine race gained as compared to others.